Search Results
33 items found for "glucose tolerance"
- In vivo metabolic effects after acute activation of skeletal muscle G s signaling
acute activation of Gs signaling in skeletal muscle (SKM) in vivo and its contribution to whole-body glucose Results: Acute stimulation of GsD signaling in SKM impaired glucose tolerance in lean and obese mice by decreasing glucose uptake selectively into SKM. Clenbuterol injection improved glucose tolerance by increasing insulin secretion in lean mice. UCN2 injection resulted in decreased glucose tolerance associated with lower plasma insulin levels.
- Recurrent hypoglycemia increases hepatic gluconeogenesis without affecting glycogen metabolism or sy
Objective: To study the effects of RH on metabolic pathways associated with glucose counterregulation Further, we performed pyruvate and lactate tolerance tests to assess gluconeogenesis. Finally, we conducted epinephrine tolerance test to investigate systemic glycemic excursions to counterregulatory
- Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota..
are thought to calibrate glucagon-like peptide 1 (GLP-1) bioavailability, thereby regulating systemic glucose the gut IEL GLP-1 receptor (GLP-1R) is not required for enteroendocrine L cell GLP-1 secretion and glucose Moreover, independent of glucose control or weight loss, the anti-inflammatory actions of GLP-1RAs require
- Glucagon receptor-mediated regulation of gluconeogenic gene transcription is endocytosis-dependent..
if this is true for the glucagon receptor (GCGR), which mediates physiological regulation of hepatic glucose
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
The GLP-1R, a class B1 GPCR, is integral to metabolic regulation, particularly in glucose homeostasis lower insulin release compared to exendin, both ligands exhibit similar efficacy in lowering blood glucose
- Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone...
improved action of the preproglucagon-derived hormones, glucagon, glucagon-like peptide-1 (GLP-1), and glucose-dependent
- ADGRL3 genomic variation implicated in neurogenesis and ADHD links functional effects to the...
common extracellular domain of the secretin-like GPCRs family), showed that HRM interacts with the Glucose-dependent
- Obesity-induced changes in human islet G protein-coupled receptor expression: Implications for ...
The islets of Langerhans are central to appropriate glucose homeostasis through their secretion of insulin
- Effect Delta-9-tetrahydrocannabinol and cannabidiol on milk proteins and lipid levels in HC11 cells
10μM THC and 10μM CBD reduced mRNA levels of milk proteins (CSN2 and WAP) , lipid synthesizing and glucose
- G protein-coupled receptor interactions and modification of signalling involving the ghrelin ...
of GHSR1a now extend to regulation of neurogenesis, learning and memory, gastrointestinal motility, glucose
- 📰 GPCR Weekly News, June 3 to June 9, 2024
for breast cancer GPCR Activation and Signaling The TAS1R2 G-protein-coupled receptor is an ambient glucose
- 📰 GPCR Weekly News, April 3 to 9, 2023
is exempt from TGFβ-mediated antifibrotic GPCR landscape tampering in lung fibroblasts. βHB inhibits glucose-induced
- 📰 GPCR Weekly News, September 25 to October 1, 2023
Antipsychotic displays dual GPCR binding mode GPCRs in Cardiology, Endocrinology, and Taste An extracellular glucose
- 📰 GPCR Weekly News, May 27 to June 2, 2024
Caenorhabditis elegans Comparison of infectious complications with BCMA-directed therapies in multiple myeloma Glucose
- 📰 GPCR Weekly News, May 6 to 12, 2024
Receptor (GPCR) Antibodies Treated With Therapeutic Plasma Exchange SUCNR1 regulates insulin secretion and glucose
- Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain
2021 "3-part randomized, double-blind, placebo-controlled Phase 1 study will evaluate TRV045 safety, tolerability
- Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and...
Favorable safety, tolerability and pharmacokinetic results from the trial warrant further investigation
- Search for safer pain relief advances with new engineered compounds
November 2021 " Chronic use of most opioids causes tolerance; the new compounds avoid this and other
- Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in...
announced positive topline results from its Phase 3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability
- APEX2/AUR Biosensor: A Powerful Tool for Protein Interaction and Trafficking
of molecular tools to study GPCR trafficking in real-time opens new avenues for understanding drug tolerance
- Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine...
announced positive top-line data from its Phase 3 KINECT-HD study evaluating the efficacy, safety and tolerability
- Targeted Therapies to Reduce Side Effects in Modern Drug Development
drugs to evaluated for potential toxicities and side effects, and these key factors must be deemed tolerable
- Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment ...
The Phase 1 study will assess the safety, tolerability and pharmacokinetics of CFTX-1554 in healthy subjects
- Focusing on the role of secretin/adhesion (Class B) G protein-coupled receptors in placental...
placentation, uteroplacental malperfusion, oxidative stress, endoplasmic reticulum stress, dysregulated immune tolerance
- Targeted Drug Design through GPCR Mutagenesis: Insights from β2AR
residues critical for β2AR function are under intense selective pressure, while others are more mutation-tolerant
- 📰 GPCR Weekly News, January 16 to 22, 2023
Cannabinoid tolerance in S426A/S430A x beta-arrestin 2 knock-out double mutant mice.
- 📰 GPCR Weekly News, October 16 to 22, 2023
of a human cell surface protein in yeast cells Trevena Reports Favorable TRV045 Topline Safety and Tolerability
- 📢 Early Bird Registration Ends Tomorrow! | Sep 16 - 22, 2024
Maxion Therapeutics) – BioLeader Interview Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability